Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Income from Continuing Operations (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Income from Continuing Operations for 16 consecutive years, with 66145000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 75.34% to 66145000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 28422000.0 through Sep 2025, up 54.77% year-over-year, with the annual reading at 438000.0 for FY2024, 99.06% up from the prior year.
  • Income from Continuing Operations hit 66145000.0 in Q4 2025 for Perspective Therapeutics, up from 25969000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 66145000.0 in Q4 2025 to a low of 25969000.0 in Q3 2025.
  • Historically, Income from Continuing Operations has averaged 3138500.0 across 5 years, with a median of 5701500.0 in 2022.
  • Biggest YoY gain for Income from Continuing Operations was 252.88% in 2024; the steepest drop was 1179.91% in 2024.
  • Year by year, Income from Continuing Operations stood at 1604000.0 in 2021, then tumbled by 357.29% to 7335000.0 in 2022, then tumbled by 236.4% to 24675000.0 in 2023, then soared by 252.88% to 37723000.0 in 2024, then skyrocketed by 75.34% to 66145000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CATX at 66145000.0 in Q4 2025, 25969000.0 in Q3 2025, and 21999000.0 in Q2 2025.